Biopharma | November 14, 2025
Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Moraine will serve as OTSAW’s exclusive distributor in Japan, deploying the Camello+ autonomous mobile robot and TransCar autonomous guided vehicle to support hospital logistics
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Poviztra is a second brand of Wegovy
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Subscribe To Our Newsletter & Stay Updated
